GlaxoSmithKline's experimental treatment of belantamab mafodotin exhibited a meaningful response among patients with multiple myeloma who have undergone three prior treatment options. GSK also announced plans to seek regulatory approval for the drug later this year.
GSK unveils data on study for myeloma drug belantamab mafodotin
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.